FDA-cleared profile

DeepBT Detector-Plus

Aitewan Biomedical Technology, Inc. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.

Clinical role
DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
Images and patients
Radiotherapy Planning Imaging · Brain tumors, including metastases, meningiomas, and acoustic neuromas
Key limitation
Keep in mind: The clinician must confirm and modify contours in the treatment-planning system; adult population and listed tumor scope are not extended.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Brain tumors, including metastases, meningiomas, and acoustic neuromas Input: CT or MR treatment-planning images, target structures, organs-at-risk information, and other labeled planning inputs.
  • Who uses it?Intended users: Radiation oncologists, medical physicists, dosimetrists, and other qualified professionals within the exact labeled treatment-planning workflow.
  • What does the software produce?Output: Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.
  • What is its most important limitation?Key limitation: The clinician must confirm and modify contours in the treatment-planning system; adult population and listed tumor scope are not extended.

Clinical takeaway. Clinical role: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a multicenter, multinational, retrospective standalone study of 136 cases with 360 lesions from 16 institutions (15 in the US and 1 non-US), with ground truth by consensus of three US board-certified radiologists. With bi-parametric MR images (T1W+C and T2W), lesion-wise sensitivity was 88.6% (95% CI 85.3% to 91.9%), false positive rate 0.537 tumors/case, and lesion-wise Dice coefficient 0.809 (0.793 to 0.824); with single-parametric images, 88.3%, 0.787 tumors/case and 0.804. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
CT or MR treatment-planning images, target structures, organs-at-risk information, and other labeled planning inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation-oncology planning and review environments within hospitals or other professional treatment facilities.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiation oncologists, medical physicists, dosimetrists, and other qualified professionals within the exact labeled treatment-planning workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The clinician must confirm and modify contours in the treatment-planning system; adult population and listed tumor scope are not extended.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports a multicenter, multinational, retrospective standalone study of 136 cases with 360 lesions from 16 institutions (15 in the US and 1 non-US), with ground truth by consensus of three US board-certified radiologists. With bi-parametric MR images (T1W+C and T2W), lesion-wise sensitivity was 88.6% (95% CI 85.3% to 91.9%), false positive rate 0.537 tumors/case, and lesion-wise Dice coefficient 0.809 (0.793 to 0.824); with single-parametric images, 88.3%, 0.787 tumors/case and 0.804. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "AItewan conducted a multicenter, multinational, retrospective study to evaluate the standalone analytical performance of the artificial intelligence software" … "The test dataset consisted of 136 cases with 360 lesions, retrospectively collected from 16 different institutions (15 in the US and 1 non-US).". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports a multicenter, multinational, retrospective standalone study of 136 cases with 360 lesions from 16 institutions (15 in the US and 1 non-US), with ground truth by consensus of three US board-certified radiologists. With bi-parametric MR images (T1W+C and T2W), lesion-wise sensitivity was 88.6% (95% CI 85.3% to 91.9%), false positive rate 0.537 tumors/case, and lesion-wise Dice coefficient 0.809 (0.793 to 0.824); with single-parametric images, 88.3%, 0.787 tumors/case and 0.804. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "AItewan conducted a multicenter, multinational, retrospective study to evaluate the standalone analytical performance of the artificial intelligence software" … "The test dataset consisted of 136 cases with 360 lesions, retrospectively collected from 16 different institutions (15 in the US and 1 non-US).". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Standalone lesion-wise sensitivity for brain tumors on 136 cases with 360 lesions: 88.6% (95% CI 85.3% to 91.9%) with bi-parametric MR images (T1W+C and T2W); 88.3% (95% CI 85.0% to 91.6%) with single-parametric MR images (T1W+C).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The test dataset consisted of 136 cases with 360 lesions, retrospectively collected from 16 different institutions (15 in the US and 1 non-US)." … "Table 2. Performance data of bi-parametric MR images (T1W+C and T2W) Performance Metrics Overall Value 95% Confidence Interval Lesion-wise Sensitivity 88.6% 85.3% to 91.9%". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact-product, version-specific specificity endpoint was established for this submission in the evidence set.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252190 FDA evidence package for DeepBT Detector-Plus

  • DesignFDA submission-level decision material with device, software, performance, safety, and/or usability verification as applicable; not independent clinical validation.
  • PopulationPopulation and workflow are limited to the exact FDA labeling summarized for this submission.
  • Scopeexact submission
  • Tested versionExact FDA submission release; version not separately stated in the public decision material
  • IndependenceSponsor or vendor study

K252190

Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252190 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Reviewed CMS material is not a product-specific price or coverage determination; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: CT or MR treatment-planning images, target structures, organs-at-risk information, and other labeled planning inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K252190: DeepBT Detector-Plus

  2. Routing

    Source context, not route validation: Produces initial contours for review and editing in a compatible DICOM treatment-planning system or workstation; local import, export, and approval workflow require acceptance.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K252190: DeepBT Detector-Plus

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Deployment details for the exact cleared configuration are not established in the public FDA decision material.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K252190: DeepBT Detector-Plus

  5. Viewer/worklist/report

    Unresolved route: Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K252190: DeepBT Detector-Plus

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Produces initial contours for review and editing in a compatible DICOM treatment-planning system or workstation; local import, export, and approval workflow require acceptance.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K252190 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Produces initial contours for review and editing in a compatible DICOM treatment-planning system or workstation; local import, export, and approval workflow require acceptance.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The clinician must confirm and modify contours in the treatment-planning system; adult population and listed tumor scope are not extended.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the evidence set; productivity or value claims require local evidence.

Lifecycle monitoring

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.

exact submission · checked 2026-09-04

Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252190
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Brain tumors, including metastases, meningiomas, and acoustic neuromas
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-04-10
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, fda decision summary, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not verified - checked 2026-09-04 - Exact FDA submission

    Deployment details for the exact cleared configuration are not established in the public FDA decision material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission

    Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K252190: DeepBT Detector-Plus

    U.S. Food and Drug Administration - Published 2026-04-10 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

Research history

  1. K252190 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K212915

MVision AI Segmentation

MVision AI

Authorized purpose: MVision AI Segmentation automatically generates initial contours from CT images for radiotherapy planning; the contours are transferred for professional visualization, review, modification, and approval, and the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.

Modality
Radiotherapy Planning Imaging
Anatomy
Head and neck, brain, breast, lung and abdomen, male pelvis, and female pelvis structures
Decision
2022-05-03
FDA-cleared K252304

syngo.via RT Image Suite VC10

Varian Medical Systems, Inc.

Authorized purpose: syngo.via RT Image Suite VC10 provides three-dimensional and four-dimensional multimodality visualization, registration, fusion, contouring, and planning support for radiation-treatment preparation.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain, pelvis, thorax, abdomen, targets, organs at risk, and moving tumors or organs
Decision
2026-03-18
FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K250427

TAIMedImg DeepMets

Taiwan Medical Imaging Co., Ltd.

Authorized purpose: TAIMedImg DeepMets assists trained professionals by providing initial gross-tumor-volume contours on axial contrast-enhanced T1 brain MR images for radiation-treatment planning in adults with known brain metastases; the contours require thorough review and are not a replacement for manual contouring.

Modality
Radiotherapy Planning Imaging
Anatomy
Brain metastases in adults
Decision
2025-05-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history